Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to demonstrate that following eight weeks of treatment
the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line
therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the
monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe
hypertension. A key secondary objective is to identify the duration of treatment required to
demonstrate the superiority of the FDC over both of the monotherapies.